Sarepta Therapeutics (NASDAQ:SRPT) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT). In a filing disclosed on May 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Sarepta Therapeutics stock on April 14th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Beiersdorf Aktiengesellschaft OTCMKTS: BDRFF on 5/2/2025.
• Purchased $1,001 - $15,000 in shares of Alkami Technology NASDAQ: ALKT on 4/30/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DXC Technology NYSE: DXC on 4/29/2025.
• Sold $1,001 - $15,000 in shares of DOW NYSE: DOW on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Zions Bancorporation, National Association NASDAQ: ZION on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of O'Reilly Automotive NASDAQ: ORLY on 4/29/2025.
• Purchased $1,001 - $15,000 in shares of McKesson NYSE: MCK on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 4/29/2025.
• Sold $1,001 - $15,000 in shares of Humana NYSE: HUM on 4/29/2025.

Sarepta Therapeutics Price Performance

SRPT stock traded up $0.48 during trading on Tuesday, hitting $36.85. 2,460,191 shares of the company's stock traded hands, compared to its average volume of 2,288,341. Sarepta Therapeutics, Inc. has a 52 week low of $34.90 and a 52 week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business has a fifty day simple moving average of $65.42 and a 200 day simple moving average of $99.77. The stock has a market capitalization of $3.62 billion, a price-to-earnings ratio of 29.48 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a net margin of 7.43% and a return on equity of 11.00%. The company's quarterly revenue was up 80.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.73 EPS. As a group, research analysts expect that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

SRPT has been the subject of several recent analyst reports. Cantor Fitzgerald reduced their price objective on shares of Sarepta Therapeutics from $163.00 to $81.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Wells Fargo & Company dropped their target price on shares of Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. HC Wainwright dropped their target price on shares of Sarepta Therapeutics from $75.00 to $40.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Finally, Guggenheim dropped their target price on Sarepta Therapeutics from $112.00 to $98.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Six research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $131.22.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tidal Investments LLC boosted its holdings in shares of Sarepta Therapeutics by 91.2% in the 3rd quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company's stock valued at $704,000 after buying an additional 2,688 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Sarepta Therapeutics by 27.7% in the 4th quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company's stock valued at $104,000 after purchasing an additional 185 shares during the last quarter. Everence Capital Management Inc. purchased a new position in Sarepta Therapeutics during the 4th quarter worth $344,000. Nordea Investment Management AB raised its position in Sarepta Therapeutics by 19.1% during the 4th quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock worth $8,228,000 after buying an additional 10,815 shares during the last quarter. Finally, ORG Partners LLC raised its position in Sarepta Therapeutics by 17.6% during the 4th quarter. ORG Partners LLC now owns 2,000 shares of the biotechnology company's stock worth $243,000 after buying an additional 300 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Activity

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 7.70% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.